Mirena (Levonorgestrel)

Levonorgestrel released from Mirena acts locally within the uterus. It thickens cervical mucus to block sperm entry, suppresses the growth of the endometrial lining, and may inhibit ovulation by reducing the release of gonadotropins. This combination creates an environment that prevents pregnancy and reduces menstrual bleeding.

Mirena contains a fixed 52 mg of levonorgestrel within the intrauterine system. The device is inserted once and provides contraceptive protection for up to five years. The exact dosing schedule and timing of replacement are determined by the prescribing clinician based on individual patient needs.

Mirena is not intended for use during pregnancy; if pregnancy occurs, the device should be removed promptly. For breastfeeding women, Mirena is generally considered compatible after insertion, but clinicians should evaluate each case individually and discuss any potential risks with the patient.

To order Mirena, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to Mirena is the copper intrauterine device, which provides non‑hormonal contraception. Mirena offers hormonal benefits such as reduced menstrual bleeding and pain relief, whereas copper IUDs may increase menstrual flow. Choice depends on patient preference, medical history, and tolerance of hormonal effects.

Mirena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight, and physical damage. Handling should be performed by trained healthcare professionals using aseptic technique during insertion.

Mirena is inserted into the uterine cavity by a qualified clinician using a specialized inserter. The procedure is performed in a clinical setting under sterile conditions. After placement, the device remains in situ for up to five years, after which it can be removed or replaced.

Serious risks include uterine perforation during insertion, spontaneous expulsion of the device, and pelvic infection such as pelvic inflammatory disease. If pregnancy occurs while Mirena is in place, there is an increased risk of ectopic pregnancy. Patients should seek immediate medical attention if they experience severe abdominal pain, abnormal bleeding, or signs of infection.

Mirena is contraindicated in women with known or suspected uterine or breast cancer, active pelvic infection, unexplained vaginal bleeding, or a uterine anomaly that could impede device placement. It should also be avoided in individuals who are pregnant or who have a history of severe allergic reaction to levonorgestrel.